Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

All right. So, let's continue with these updates from Eco. Eco had a lot for us. So now we're gonna plan for long-term maintenance and relapse prevention. OK, let's get into it. Let's look at the surmount maintain trial. This is Cruze's epitype for the maintenance of body weight reduction. And in this design, this was a phase 3B randomized parallel arm double-blind placebo-controlled 112-week trial. Say that 5 times fast. Um, and we're looking at adults with a BMI of greater than 30 kg per meter squared and, or those that have a greater than 27 kg per meter squared with one obesity-related complication. This was a 60-week open label weight loss period, which means that they all received trazepetide on a weekly basis at a dose of either 10 or 15 mg. And then after that period, they went into a double bind period where they were randomized 3 to 3 to 2, which means they got either ruzepeide at a 10 or 15 mg dose, ruzepeide at a 5 mg dose, or placebo. So that was how the randomization occurred. There was a rescue through zeetide, a restart or increased dose from week 84. So after they went to that randomization period, after the 60 and then the 52 week, then there was an 84 week rescue period, OK? The primary endpoint was the percent change from baseline and body weight at week 112, and the secondary endpoint was maintenance at week 112 and those who reached body weight plateau. So in this particular results, we're looking at the change in body weight over time. And as you can see, we have that initial weight loss period, that first 60-week period where everyone was receiving medication and as expected, we see a sharp decline. And then we get this randomization to those three different groups. The group that stayed on the 10 to 15, which achieves the 22.4% weight loss. The group that was switched over to 5 mg. And then the group that was switched over to placebo, OK? That's what we see. Now, let's talk about the maintenance of body weight reduction, that secondary endpoint. Remember, we have some different groups. Those that were kept on medication, obviously maintained the most. Those that were switched um or reduced, achieved less weight. Um, and that's really important for us to notice. It's not surprising. Um, what we do see is that the cardio metabolic parameters, those that continued on, um, trapeide led to preserved improvement in BMI, waist circumference, BP, and lipids with greater improvement in quality of life indices on the SF 336. Reducing the dose of recepatide to 5 mg maintained clinically meaning benefits. Maybe not as much weight loss, but they still had some improvement in their anthropometric measures and um these other metabolic parameters. Inter appetite discontinuation led to substantial weight regain. Uh, we saw that in that previous slide. Um, but greater reversal of also cardio metabolic benefits. Safety, most commonly reported adverse effects were with his appetite were GI related is to be expected, and generally mild to moderate in severity. The safety results were overall consistent with known trageetite safety profile. So, what are some big callouts from this study? The Surmount Maintained trial, continued rezepeide at um maintenance dose, resulted in a sustained maintenance of body weight reduction and related health benefits. If you're staying on ruzepetide and if that's not feasible, reduction to a 5 mg does provide a valuable alternative to discontinuation. And the surmount Maintained is the first study to provide evidence associated with reducing treatment intensity to inform patient-centered obesity care. All right. So, well, if we weren't looking at the surmount maintain, let's go to the Atane maintain. Don't get them confused because they are not the same trial, but produced by the same company. So, this is orhoglyron for the maintenance of body weight reduction. This is double-blind randomized phase 3B trial, the A mainchain trial. In the background is that orhoglyron is an oral small molecule non-peptide GLP-1 receptor agonist. The half-life is about 48 hours. And, um, as a non-peptide, it can be taken plus or minus food plus water. Adults who completed the surmount trial, that's the Truzepeide trial of study treatment and achieved a 5% body weight reduction, were allowed to compete, to participate in this particular trial. So, let's look at the um attain, maintain trial. Cohort one is the treatment group of druzepeide from surmount 5. Cohort two is simaglatide. So they compared themselves to um Novo, right? So this is a dual agonist um with the GLP1 and the GIP and now we have a single agonist, and we're comparing, OK? What happens. So, what's the, what do, what do we see happen? So we do trazepetide over to orphoglipron and simaglatide over to orroglipron. And what we see is, remember that P value, we need to be less than 0.05. Um, what we see is, obviously, when we switch over to orthoglipron, we do see some shifts in weight. Um, 78% of surmount 5 weight reduction was maintained on orthoglyron. Um, you can see more weight reduction was maintained with simaglatide, um, when they were switched to orthoglyron. So that's interesting that they achieved that. Um, what about this, you know, difference, right? This 5% difference versus the 1% difference when you are comparing the switch from recepatide to orthoglyron versus simmaglatide to orthoglyron. I think it's important for us to note this difference, but that is the change in body weight during the 18 Maintain trial. Um, so let's look at the cardio metabolic parameters. All the following sustained with the switch to orthoglyron, the reduction in waist circumference, the improvements in the lipid profile, the decrease in the um systolic BP. With safety, it was overall consistent with previous orhoglyron studies and GLP ones. Um, no hepatic safety signals were observed. The switch to 9 mg of orhoglypron after a maintenance dose of injectable therapy was generally well tolerated. So the key message here, do not stop therapy. So, in the 18, maintained switching from injectablestrazepetide or staglatide to daily orthoglyron led to sustaining most of the lost weight and associated improvement in cardio metabolic parameters, which were achieved in the surmount trial. All right. We're shifting gears. We're not talking about a medication now that's a GLP-1. We're moving on to body composition. This is really important because we know about the lean mass that can be lost during the use of GLP-1. So, now, let's look at body composition changes with six-month withdrawal from simaglatide and or bamagroab. It's a monoclonal antibody, treatments in adults with obesity and the Believe study extension. So theaggramab is an investigational antibody to activin type 2 receptors that blocks activin and myostatin pathways in the muscle and adipose tissue. It increases skeletal muscle and decreases fat mass and overweight and obesity with type 2 diabetes. Now, in this phase 2EE trial in overweight and obesity without type 2 diabetes, theaggramab plus the magnetide resulted in additive fat loss and muscle preservation. And so, what they sought to do was to assess the effect of 6-month treatment withdrawal after 72 weeks of treatment with simaglatide and or bimagumab on body composition and other endpoints and believe. There is a 1% change from baseline and body weight, fat mass, and lean mass, and visceral adipose tissue by DEXA, along with um highly sensitive C-reactive protein. Now, we're gonna look at body weight change from baseline to week 104. And I want us to look at this because you can see the dosing from placebo all the way up to 30 mg per kilogram of Imaggrama plus 2.4 mg of simaglatide. And I think you can see that if we look at this, that we're seeing some significant changes in lean skeletal muscle over time, where we see a gain. Here, we're looking at total body fat mass, total lean mass. Now, notice how we see a difference here in total lean mass. We're looking at visceral adipose tissue and highly selective C-reactive protein. So, in the believed treatment um to week 72, it resulted in similar fat loss and greater reductions in visceral adipose tissue and highly sensitive um C-reactive protein with bimagumab versus simaglatide. There was an increase in lean mass with bimaggramab and a decrease in simmaglatide, which is to be expected cause we talked about that at the outset. There was a preservation when they were combined. Following 6 months of treatment withdrawal, lean mass preservation was better after bimagumab. Fat mass and weight reduction were better after the combination, and the partial weight regain following somaglatite treatment withdrawal had a similar fat to lean ratio as the weight loss, suggesting that stopping appetite regulating agents may not lead to preferential fat regain in this population.